Category Archives: OTC

Emaji, Inc. (EMJI: OTC Pink Current) | CORRECTION: CORRECTION: Emaji Corporate Finance Update April 2015

CORRECTION: CORRECTION: Emaji Corporate Finance Update April 2015

Apr 26, 2015

OTC Disclosure News Service

Irvine, CA

This release includes additional documents. Select the link(s) below to view.

emajicorprelease final 4 27 15 corporate finance .pdf

Copyright © 2015 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/EMJI/news?id=102869

Guided Therapeutics, Inc. (GTHP: OTCQB) | Canadian Pilot Programs Initiated with LuViva® Advanced Cervical Scan for Provincial-level Cancer Care Support

Canadian Pilot Programs Initiated with LuViva® Advanced Cervical Scan for Provincial-level Cancer Care Support

Apr 24, 2015

OTC Disclosure News Service

Guided
Therapeutics, Inc.
(OTCBB: GTHP) (OTCQB: GTHP), announced today an
initiative for procuring provincial-level support for its LuViva
Advanced Cervical Scan. The initiative is based on discussions with
women’s healthcare experts across Canada, whose interest has increased
after reviewing positive results from two previous evaluations completed
in Halifax, Nova Scotia, with Dr. James Bentley and most recently in
London, Ontario, with Drs. Robert DiCecco and Monique Bertrand.

“I was impressed with the accuracy of LuViva and that our results so
closely mirrored those of Dr. Bentley,” said Dr. DiCecco. “I definitely
see a place for LuViva in our clinic to aid in the management of
cervical disease, by reducing unnecessary procedures and identifying
women at higher risk.”

“The key to making LuViva a success is to engage large government health
care systems, where the cost savings and patient benefits are
demonstrated on a large scale,” said Gene Cartwright, CEO and President
of Guided Therapeutics. “While working with government entities can take
time, we believe it is the best path forward for the success for both
LuViva and the company.”

Pilot programs are expected to involve up to 80 women in selected
provinces and be completed this year, with the first starting this week.
Upon successful completion of these evaluations, the company expects
that recommendations will be made as to whether to include LuViva in the
standard of care, for women at risk of cervical cancer, for the selected
provinces. There are approximately 40,000 women in Canada with abnormal
Pap tests yearly who would be eligible for a LuViva scan.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called biophotonics.
Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory
analysis or a tissue sample, and is designed to provide results
immediately, which may result in eliminating costly, painful and
unnecessary additional testing. LuViva is intended for use with women
who have undergone initial screening and are called back for follow up
with a colposcopy examination, which in many cases, involves taking a
biopsy of the cervix. It has also been used in clinical studies in
Turkey and Nigeria as a means to screen women for cervical cancer where
the availability of infrastructure necessary for Pap and HPV testing is
restricted. The device is used in conjunction with the LuViva® Cervical
Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a
rapid and painless testing platform based on its patented biophotonic
technology that utilizes light for the early detection of disease at the
cellular level. The Company’s first product is the LuViva® Advanced
Cervical Scan, a non-invasive device used to detect cervical disease
instantly and at the point of care. In a multi-center clinical trial,
with women at risk for cervical disease, the technology was able to
detect cervical cancer up to two years earlier than conventional
modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced
Cervical Scan is an investigational device and is limited by federal law
to investigational use. LuViva, the wave logo and “Early detection,
better outcomes” are registered trademarks owned by Guided Therapeutics,
Inc.

Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments.
The discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’
actual future experience involving any of or more of such matters and
subject areas. Such risks and uncertainties include those related to the
early stage of products in development, the uncertainty of market
acceptance of products, the uncertainty of development or effectiveness
of distribution channels, the intense competition in the medical device
industry, the uncertainty of capital to develop products, the
uncertainty of regulatory approval of products, dependence on licensed
intellectual property, as well as those that are more fully described
from time to time under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including Guided Therapeutics’
Annual Report on Form 10-K for the fiscal year ended December 31, 2014,
and subsequent quarterly reports.

Copyright © 2015 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/GTHP/news?id=102857

The Graystone Company, Inc. (GYST: OTC Pink Current) | Notice of intent to purchase common stock via open market stock purchase

Notice of intent to purchase common stock via open market stock purchase

Apr 26, 2015

OTC Disclosure News Service

Las Vegas, NV

Normal
0

false
false
false

EN-US
JA
X-NONE

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}

Notice of intent to purchase common stock via open market stock
purchase

Normal
0

false
false
false

EN-US
JA
X-NONE

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}

Las
Vegas, NV — Notice is hear by given to the general public and the shareholders
of The Graystone Company GYST by Renard Properties, LLC, an affiliate of The
Graystone Company CEO and CFO Paul Howarth and under direct control of Graystone CEO and CFO Paul Howarth, to purchase up to 1.5 million shares of the companies common
stock on the open market. By making this disclosure, Renard Properties, LLC is under no obligation to
purchase these shares. The time period will start on or after April 27, 2015
and will end on June 1, 2015. 

Copyright © 2015 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/GYST/news?id=102863

Bunk Beds